Rising Prevalence of Zoonotic Diseases
The global companion animal pharmaceuticals market is projected to reach USD 19.6 billion by 2027 from USD 14.4 billion in 2022, at a CAGR of 6.3% during the forecast period. The Rising prevalence of zoonotic diseases, Rising demand for pet insurance due to growing animal health expenditure, Increasing R&D investments for animal healthcare, Initiatives by various government agencies and animal associations, High pet ownership rates worldwide are some of the factors driving the growth of these markets. However, Rising pet care costs, Limited number of new product developments, High cost of vaccines and complexities associated with storage, Growing resistance to antimicrobials and antibiotics are restraining the growth of this market to a certain extent.
The dermatologic diseases segment is projected to grow at the highest CAGR in the companion animal pharmaceuticals market
The dermatologic diseases segment is projected to grow at the highest CAGR during the forecast period. The rising need for advanced orthopedic drugs, increasing prevalence of arthritis, and growing pet population in developed and developing countries are some of the key factors driving the growth of this segment.
In the forecast period, the dogs segment holds the largest share in the animal type segment
The dogs segment accounted for the largest market share in 2021. The large share of this segment is attributed to the increasing dog population and rising ownership rate in both developed and developing countries , rising canine healthcare expenditure, increasing prevalence of zoonotic diseases and other skin allergies in dogs, and the rising number of pet insurers across the globe.
In the forecast period, by distribution channel segment, veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market
During the forecast period, the veterinary hospitals segment is expected to grow at the highest CAGR. The higher adoption of animal parasiticides, analgesic, antimicrobials and antibiotics in hospital settings, rising cases of infectious diseases, increasing number of veterinary hospitals, growing ownership rate of companion animals, and rising veterinary expenditure are some of the key factors driving the growth of this segment.
By Region, North America holds the largest share in the companion animal pharmaceuticals market, in the forecast period
By Region, In 2021, North America accounted for the largest share of the companion animal pharmaceuticals market in the forecast period, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the high adoption rate of companion animals such as dogs and cats, well-established base of animal health industries, rising animal adoption centers, rising cases of parasitic infections, the large number of hospitals and clinics, growing expenditure on animal health in the region and , growing pool of veterinarians.
A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:
- By Company Type: Tier 1 - 35%, Tier 2 - 45%, and Tier 3 - 20%
- By Designation: C-level - 35%, Director Level - 25%, and Others - 40%
- By Region: North America - 40%, Asia-Pacific - 30%, Europe - 20%, Middle East & Africa - 5%, Latin America - 5%
The prominent players in the global companion animal pharmaceuticals market are Zoetis, Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco Animal Health Incorporated (US), Eco Animal Health Group PlC (UK), Virbac (France), Dechra Pharmaceuticals PLC (UK), Vetoquinol (France), Neogen Corporation (US), Orion Group (Finland), Zenex Animal Health India Private Limited (India), Norbrook Holdings Limited (UK), Chanelle Pharma (Ireland), HIPRA (Spain), Ceva Sante Animale (France), Tianjin Ringpu Bio-Technology Co Ltd. (China), Kyoritsu Seiyaku (Japan), Endovac Animal Health (US), Indian Immunologicals Ltd (India), Ashish Life Sciences Pvt Ltd (India), Lutim Pharma Pvt Ltd (India), Biogénesis Bagó (US), Brilliant Bio Pharma (India), Intas Pharmaceuticals (India), and Vetindia Pharmaceuticals limited (India).
Research Coverage:
This research report categorizes the companion animal pharmaceuticals market by indication, by route of administration, by animal type, by distribution channel and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion animal pharmaceuticals market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the companion animal pharmaceuticals market. Competitive analysis of upcoming startups in the C4ISR market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall C4ISR market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
- Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market
Table of Contents
1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.2.1 Inclusions and Exclusions
1.2.2 Markets Covered
1.2.3 Years Considered
1.3 Currency Considered
1.4 Limitations
1.5 Stakeholders
1.6 Summary of Changes
2 Research Methodology
2.1 Research Approach
2.1.1 Secondary Research
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Research
2.1.2.1 Primary Sources
2.1.2.2 Key Data from Primary Sources
2.1.2.3 Key Industry Insights
2.1.2.4 Breakdown of Primaries
2.2 Market Size Estimation
2.3 Data Triangulation Approach
2.4 Market Share Estimation
2.5 Assumptions for Study
2.6 Risk Assessment
2.7 Limitations
2.7.1 Methodology-Related Limitations
2.7.2 Scope-Related Limitations
2.8 Impact of Recession
3 Executive Summary
4 Premium Insights
4.1 Companion Animal Pharmaceuticals Market Overview
4.2 Europe: Market, by Indication and Country (2021)
4.3 Market: Geographic Growth Opportunities
4.4 Market, by Region (2022-2027)
4.5 Market: Developed Vs. Emerging Markets
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Rising Prevalence of Zoonotic Diseases
5.2.1.2 Rising Demand for Pet Insurance due to Growing Animal Health Expenditure
5.2.1.3 Increasing R&D Investments for Animal Healthcare
5.2.1.4 Rising Awareness Initiatives by Government Agencies and Animal Welfare Organizations
5.2.1.5 High Pet Ownership Rates Worldwide
5.2.2 Market Restraints
5.2.2.1 Rising Pet Care Costs
5.2.2.2 Limited Number of Novel Pharmaceuticals for Veterinary Care
5.2.2.3 High Cost of Vaccines and Complexities Associated with Storage
5.2.2.4 Growing Resistance to Antimicrobials and Antibiotics
5.2.3 Market Opportunities
5.2.3.1 Lucrative Growth Opportunities in Emerging Markets
5.2.3.2 Growing Prevalence of Chronic Animal Diseases
5.2.3.3 Rising Technological Advancements in Vaccine Manufacturing
5.2.4 Market Challenges
5.2.4.1 Stringent Regulatory Approval Process for Pharmaceuticals
5.2.4.2 Limited Awareness of Vaccine Coverage
5.2.4.3 Misdiagnosis due to Diversity of Parasites
5.2.4.4 Low Animal Healthcare Expenditure in Emerging Countries
6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Rising Acquisitions of Smaller Companies by Global Players
6.2.2 Increasing Product Innovations for Animal Healthcare Products
6.2.3 Expanding Veterinary Businesses Worldwide
6.3 Porter's Five Forces Analysis
6.3.1 Threat of New Entrants
6.3.2 Threat of Substitutes
6.3.3 Bargaining Power of Suppliers
6.3.4 Bargaining Power of Buyers
6.3.5 Intensity of Competitive Rivalry
6.4 Regulatory Analysis
6.4.1 Regulatory Bodies, Government Agencies, and Other Organizations
6.4.1.1 US
6.4.1.2 Europe
6.4.1.3 Rest of the World
6.5 Value Chain Analysis
6.6 Supply Chain Analysis
6.7 Ecosystem Analysis
6.7.1 Market: Ecosystem Analysis
6.8 Patent Analysis
6.8.1 Market: Patent Analysis Trends
6.8.2 Top Applicants (Companies/Institutions) for Companion Animal Pharmaceuticals
6.8.3 Jurisdiction Analysis: Top Applicants (Countries) for Companion Animal Pharmaceuticals
6.9 Pricing Analysis
6.10 Key Conferences and Events from 2023 to 2024
6.11 Key Stakeholders & Buying Criteria
6.11.1 Key Stakeholders in Buying Process
6.12 Trade Analysis
7 Companion Animal Pharmaceuticals Market, by Indication
7.1 Introduction
7.2 Infectious Diseases
7.2.1 Parasiticides
7.2.1.1 Growing Regulatory Guidelines to Control Parasite-Related Diseases to Fuel Market
7.2.2 Vaccines
7.2.2.1 Growing Awareness Among Pet Owners for Canine & Feline Vaccines to Drive Market
7.2.3 Antibiotics and Antimicrobials
7.2.3.1 Effective Prevention for Clinical and Subclinical Diseases in Companion Animals to Fuel Uptake
7.2.4 Others
7.3 Dermatologic Diseases
7.3.1 Rising Cases of Dermatitis due to Nutritional Deficiencies to Drive Market
7.4 Pain
7.4.1 Rising Demand for Anti-Inflammatory Drugs and Opioids to Drive Market
7.5 Orthopedic Diseases
7.5.1 Growing Prevalence of Osteoarthritis due to Increasing Obesity in Pets to Drive Market
7.6 Behavioral Disorders
7.6.1 Increasing Awareness Among Pet Owners for Appropriate Pet Behavior to Support Market Growth
7.7 Other Indications
8 Companion Animal Pharmaceuticals Market, by Route of Administration
8.1 Introduction
8.2 Oral Administration
8.2.1 Ability to Treat a Wide Range of Diseases and Affordability to Drive Demand
8.3 Injectable Administration
8.3.1 Advantages of Complete Absorption and Bioavailability to Fuel Uptake
8.4 Topical Administration
8.4.1 Temporary Effects of Topical Drugs Compared to Oral and Parenteral Drugs to Restrain Market
9 Companion Animal Pharmaceuticals Market, by Animal Type
9.1 Introduction
9.2 Dogs
9.2.1 Rising Pet Dog Population Worldwide to Drive Market
9.3 Cats
9.3.1 Increasing R&D Activities on Feline Health to Drive Market
9.4 Horses
9.4.1 Rising Prevalence of Infectious Diseases to Support Market Growth
9.5 Other Companion Animals
10 Companion Animal Pharmaceuticals Market, by Distribution Channel
10.1 Introduction
10.2 Veterinary Hospitals
10.2.1 Growing Focus on Healthcare and Companion Animal Diagnostic Services to Drive Market
10.3 Veterinary Clinics
10.3.1 Rising Number of Private Clinical Practices to Drive Market
10.4 Retail Pharmacies
10.4.1 Accessibility of Pharmaceuticals Through Prescriptions and OTC Medication to Support Market Growth
11 Companion Animal Pharmaceuticals Market, by Region
11.1 Introduction
11.2 North America
11.2.1 North America: Recession Impact
11.2.2 US
11.2.2.1 Rising Pet Expenditure to Fuel Market
11.2.3 Canada
11.2.3.1 Increasing Pet Ownership Rates to Drive Demand for Vaccines
11.3 Europe
11.3.1 Europe: Recession Impact
11.3.2 Germany
11.3.2.1 Rising Focus on Animal Health due to Increasing Vet Practices to Drive Market
11.3.3 UK
11.3.3.1 Availability of Animal Health Insurance Policies to Fuel Market for Pharmaceuticals
11.3.4 France
11.3.4.1 Rising Prevalence of Infectious Diseases to Drive Demand for Animal Health Products
11.3.5 Spain
11.3.5.1 Increasing Adoption Rates of Dogs and Cats to Fuel Market
11.3.6 Italy
11.3.6.1 Lucrative Animal and Pet Health Sectors to Drive Market Growth
11.3.7 Rest of Europe
11.4 Asia-Pacific
11.4.1 Asia-Pacific: Recession Impact
11.4.2 China
11.4.2.1 Rising Number of Zoonotic & Infectious Diseases in Animals to Drive Market
11.4.3 Japan
11.4.3.1 Rising Demand for Imported Breeds to Support Market Growth
11.4.4 India
11.4.4.1 Rising Focus on Pet Care due to a Large Population of Domesticated Animals to Drive Market
11.4.5 South Korea
11.4.5.1 Pet Care Initiatives for Street Dogs and Cats to Fuel Market for Animal Care Products
11.4.6 Australia
11.4.6.1 Growing Awareness of Parasitic Infections to Drive Demand for Parasiticides
11.4.7 Rest of Asia-Pacific
11.5 Latin America
11.5.1 Growing Pool of Skilled Veterinarians Owing to Rising Pet Population to Drive Market
11.5.2 Latin America: Recession Impact
11.6 Middle East & Africa
11.6.1 Emerging Market for Animal Healthcare Practises to Support Uptake
11.6.2 Middle East & Africa: Recession Impact
12 Competitive Landscape
12.1 Overview
12.2 Revenue Share Analysis of Top 5 Players
12.3 Market Share Analysis
12.4 Company Evaluation Quadrant
12.4.1 Stars
12.4.2 Emerging Leaders
12.4.3 Pervasive Players
12.4.4 Participants
12.5 Startups/Sme Evaluation Quadrant
12.5.1 Progressive Companies
12.5.2 Dynamic Companies
12.5.3 Starting Blocks
12.5.4 Responsive Companies
12.6 Competitive Benchmarking
12.7 Company Geographic Footprint
12.8 Competitive Situation and Trends
12.8.1 Product Launches & Approvals
12.8.2 Deals
12.8.3 Other Developments
13 Company Profiles
13.1 Key Players
13.1.1 Zoetis Inc.
13.1.1.1 Business Overview
13.1.1.2 Products Offered
13.1.1.3 Recent Developments
13.1.2 Analyst's View
13.1.2.1 Key Strengths
13.1.2.2 Strategic Choices
13.1.2.3 Weaknesses and Competitive Threats
13.1.3 Merck & Co., Inc.
13.1.3.1 Business Overview
13.1.3.2 Products Offered
13.1.3.3 Recent Developments
13.1.3.4 Analyst's View
13.1.3.4.1 Key Strengths
13.1.3.4.2 Strategic Choices
13.1.3.4.3 Weaknesses and Competitive Threats
13.1.4 Boehringer Ingelheim International GmbH
13.1.4.1 Business Overview
13.1.4.2 Products Offered
13.1.4.3 Recent Developments
13.1.4.4 Analyst's View
13.1.4.4.1 Key Strengths
13.1.4.4.2 Strategic Choices
13.1.4.4.3 Weaknesses and Competitive Threats
13.1.5 Elanco Animal Health Incorporated
13.1.5.1 Business Overview
13.1.5.2 Products Offered
13.1.5.3 Recent Developments
13.1.6 Virbac
13.1.6.1 Business Overview
13.1.6.2 Products Offered
13.1.6.3 Recent Developments
13.1.7 Dechra Pharmaceuticals plc
13.1.7.1 Business Overview
13.1.7.2 Products Offered
13.1.7.3 Recent Developments
13.1.8 Vetoquinol
13.1.8.1 Business Overview
13.1.8.2 Products Offered
13.1.8.3 Recent Developments
13.1.9 Neogen Corporation
13.1.9.1 Business Overview
13.1.9.2 Products Offered
13.1.9.3 Recent Developments
13.1.10 Orion Group
13.1.10.1 Business Overview
13.1.10.2 Products Offered
13.1.10.3 Recent Developments
13.1.11 Eco Animal Health Group plc
13.1.11.1 Business Overview
13.1.11.2 Products Offered
13.2 Other Players
13.2.1 Zenex Animal Health India Private Limited
13.2.2 Norbrook
13.2.3 Chanelle Pharma
13.2.4 Hipra
13.2.5 Ceva Santé Animale
13.2.6 Tianjin Rinpu Bio-Technology Co., Ltd.
13.2.7 Kyoritsu Seiyaku
13.2.8 Endovac Animal Health
13.2.9 Indian Immunologicals Ltd.
13.2.10 Ashish Life Science Pvt. Ltd.
13.2.11 Pharma Pvt. Ltd.
13.2.12 Biogenesis Bago S.A.
13.2.13 Intas Pharmaceuticals
13.2.14 Brilliant Biopharma
13.2.15 Vetindia Pharmaceuticals Limited
14 Appendix
14.1 Industry Expert Insights
14.2 Discussion Guide
14.3 Knowledgestore: The Subscription Portal
14.4 Customization Options
List of Tables (183 Table)
Table 1 Exchange Rates Utilized for the Conversion to Usd
Table 2 Animal Disease Outbreaks in Asia-Pacific Countries (2013-2019)
Table 3 US: Average Premium Rates (2019-2021)
Table 4 North America: Pet Health Insurance Market, 2012-2021 (USD Million)
Table 5 Pet Population, by Animal, 2014-2020 (Million)
Table 6 Market Drivers: Impact Analysis
Table 7 Market Restraints: Impact Analysis
Table 8 Market Opportunities: Impact Analysis
Table 9 Market Challenges: Impact Analysis
Table 10 Companion Animal Pharmaceuticals Market: Major Acquisitions (2017-2022)
Table 11 Innovative Companion Animal Pharmaceutical Trends
Table 12 Porter's Five Forces Analysis
Table 13 US: Recent Developments in Regulations for Veterinary Drugs
Table 14 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 15 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 16 Rest of the World: Regulatory Bodies, Government Agencies, and Other Organizations
Table 17 Average Selling Prices of Companion Animal Pharmaceuticals by Application (USD)
Table 18 Market: Conferences and Events
Table 19 Influence of Stakeholders in Buying Process for Top 3 Applications
Table 20 Key Buying Criteria for Top 3 Applications
Table 21 Market, by Indication, 2020-2027 (USD Million)
Table 22 Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 23 Market for Infectious Diseases, by Country, 2020-2027 (USD Million)
Table 24 Market for Parasiticides, by Country, 2020-2027 (USD Million)
Table 25 Market for Vaccines, by Country, 2020-2027 (USD Million)
Table 26 Market for Antibiotics and Antimicrobials, by Country, 2020-2027 (USD Million)
Table 27 Market for Others, by Country, 2020-2027 (USD Million)
Table 28 Market for Dermatologic Diseases, by Country, 2020-2027 (USD Million)
Table 29 Market for Pain, by Country, 2020-2027 (USD Million)
Table 30 Pharmaceuticals Market for Orthopedic Diseases, by Country, 2020-2027 (USD Million)
Table 31 Market for Behavioral Disorders, by Country, 2020-2027 (USD Million)
Table 32 Market for Other Indications, by Country, 2020-2027 (USD Million)
Table 33 Routes of Administration for Key Companion Animal Pharmaceuticals
Table 34 Companion Animal Pharmaceuticals Market, by Route of Administration, 2020-2027 (USD Million)
Table 35 Market for Oral Administration, by Country, 2020-2027 (USD Million)
Table 36 Market for Injectable Administration, by Country, 2020-2027 (USD Million)
Table 37 Companion Animal Pharmaceutical Market for Topical Administration, by Country, 2020-2027 (USD Million)
Table 38 Market, by Animal Type, 2020-2027 (USD Million)
Table 39 Market for Dogs, by Country, 2020-2027 (USD Million)
Table 40 Market for Cats, by Country, 2020-2027 (USD Million)
Table 41 Horse Population, by Region, 2016-2020 (Million)
Table 42 Market for Horses, by Country, 2020-2027 (USD Million)
Table 43 Market for Other Companion Animals, by Country, 2020-2027 (USD Million)
Table 44 Market, by Distribution Channel, 2020-2027 (USD Million)
Table 45 Veterinary Visit Expenses for Cats and Dogs (Us)
Table 46 Market for Veterinary Hospitals, by Country, 2020-2027 (USD Million)
Table 47 Number of Private Clinical Practices, by Country (2019 Vs. 2021)
Table 48 Market for Veterinary Clinics, by Country, 2020-2027 (USD Million)
Table 49 Market for Retail Pharmacies, by Country, 2020-2027 (USD Million)
Table 50 Companion Animal Population, by Country, 2022 (Thousand)
Table 51 Market, by Region, 2020-2027 (USD Million)
Table 52 North America: Companion Animal Pharmaceuticals Market, by Country, 2020-2027 (USD Million)
Table 53 North America: Market, by Indication, 2020-2027 (USD Million)
Table 54 North America: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 55 North America: Market, by Route of Administration, 2020-2027 (USD Million)
Table 56 North America: Market, by Animal Type, 2020-2027 (USD Million)
Table 57 North America: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 58 US: Private Clinical Practices, by Animal Type, 2019-2021
Table 59 US: Market, by Indication, 2020-2027 (USD Million)
Table 60 US: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 61 US: Market, by Route of Administration, 2020-2027 (USD Million)
Table 62 US: Market, by Animal Type, 2020-2027 (USD Million)
Table 63 US: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 64 Canada: Companion Animal Population, 2016-2020 (Million)
Table 65 Canada: Companion Animal Pharmaceuticals Market, by Indication, 2020-2027 (USD Million)
Table 66 Canada: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 67 Canada: Market, by Route of Administration, 2020-2027 (USD Million)
Table 68 Canada: Market, by Animal Type, 2020-2027 (USD Million)
Table 69 Canada: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 70 Europe: Companion Animal Population, 2021 (Million)
Table 71 Europe: Number of Veterinarians, 2014-2020
Table 72 Europe: Market, by Country, 2020-2027 (USD Million)
Table 73 Europe: Market, by Indication, 2020-2027 (USD Million)
Table 74 Europe: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 75 Europe: Market, by Route of Administration, 2020-2027 (USD Million)
Table 76 Europe: Market, by Animal Type, 2020-2027 (USD Million)
Table 77 Europe: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 78 Germany: Companion Animal Population, 2016-2021 (Million)
Table 79 Germany: Number of Veterinarians, 2015 Vs. 2020
Table 80 Germany: Companion Animal Pharmaceuticals Market, by Indication, 2020-2027 (USD Million)
Table 81 Germany: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 82 Germany: Market, by Route of Administration, 2020-2027 (USD Million)
Table 83 Germany: Market, by Animal Type, 2020-2027 (USD Million)
Table 84 Germany: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 85 UK: Companion Animal Population, 2017-2020 (Million)
Table 86 UK: Number of Veterinarians, 2016 Vs. 2020
Table 87 UK: Market, by Indication, 2020-2027 (USD Million)
Table 88 UK: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 89 UK: Market, by Route of Administration, 2020-2027 (USD Million)
Table 90 UK: Market, by Animal Type, 2020-2027 (USD Million)
Table 91 UK: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 92 France: Companion Animal Population, 2010-2021 (Million)
Table 93 France: Companion Animal Pharmaceuticals Market, by Indication, 2020-2027 (USD Million)
Table 94 France: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 95 France: Market, by Route of Administration, 2020-2027 (USD Million)
Table 96 France: Market, by Animal Type, 2020-2027 (USD Million)
Table 97 France: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 98 Spain: Companion Animal Population, 2016-2021 (Million)
Table 99 Spain: Market, by Indication, 2020-2027 (USD Million)
Table 100 Spain: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 101 Spain: Market, by Route of Administration, 2020-2027 (USD Million)
Table 102 Spain: Market, by Animal Type, 2020-2027 (USD Million)
Table 103 Spain: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 104 Italy: Pet Population, 2017-2021 (Million)
Table 105 Italy: Companion Animal Pharmaceuticals Market, by Indication, 2020-2027 (USD Million)
Table 106 Italy: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 107 Italy: Market, by Route of Administration, 2020-2027 (USD Million)
Table 108 Italy: Market, by Animal Type, 2020-2027 (USD Million)
Table 109 Italy: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 110 Rest of Europe: Companion Animal Ownership, 2018 (Million)
Table 111 Rest of Europe: Number of Veterinarians and Paraveterinarians, 2019 Vs. 2020
Table 112 Rest of Europe: Market, by Indication, 2020-2027 (USD Million)
Table 113 Rest of Europe: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 114 Rest of Europe: Market, by Route of Administration, 2020-2027 (USD Million)
Table 115 Rest of Europe: Market, by Animal Type, 2020-2027 (USD Million)
Table 116 Rest of Europe: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 117 Asia-Pacific: Companion Animal Pharmaceuticals Market, by Country, 2020-2027 (USD Million)
Table 118 Asia-Pacific: Market, by Indication, 2020-2027 (USD Million)
Table 119 Asia-Pacific: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 120 Asia-Pacific: Market, by Route of Administration, 2020-2027 (USD Million)
Table 121 Asia-Pacific: Market, by Animal Type, 2020-2027 (USD Million)
Table 122 Asia-Pacific: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 123 China: Market, by Indication, 2020-2027 (USD Million)
Table 124 China: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 125 China: Market, by Route of Administration, 2020-2027 (USD Million)
Table 126 China: Market, by Animal Type, 2020-2027 (USD Million)
Table 127 China: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 128 Japan: Domesticated Dog and Cat Population, 2012-2020 (Thousand)
Table 129 Japan: Companion Animal Pharmaceuticals Market, by Indication, 2020-2027 (USD Million)
Table 130 Japan: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 131 Japan: Market, by Route of Administration, 2020-2027 (USD Million)
Table 132 Japan: Market, by Animal Type, 2020-2027 (USD Million)
Table 133 Japan: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 134 India: Market, by Indication, 2020-2027 (USD Million)
Table 135 India: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 136 India: Market, by Route of Administration, 2020-2027 (USD Million)
Table 137 India: Market, by Animal Type, 2020-2027 (USD Million)
Table 138 India: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 139 South Korea: Companion Animal Pharmaceuticals Market, by Indication, 2020-2027 (USD Million)
Table 140 South Korea: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 141 South Korea: Market, by Route of Administration, 2020-2027 (USD Million)
Table 142 South Korea: Market, by Animal Type, 2020-2027 (USD Million)
Table 143 South Korea: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 144 Australia: Market, by Indication, 2020-2027 (USD Million)
Table 145 Australia: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 146 Australia: Market, by Route of Administration, 2020-2027 (USD Million)
Table 147 Australia: Market, by Animal Type, 2020-2027 (USD Million)
Table 148 Australia: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 149 Rest of Asia-Pacific: Number of Veterinarians, 2012-2021
Table 150 Rest of Asia-Pacific: Companion Animal Pharmaceuticals Market, by Indication, 2020-2027 (USD Million)
Table 151 Rest of Asia-Pacific: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 152 Rest of Asia-Pacific: Market, by Route of Administration, 2020-2027 (USD Million)
Table 153 Rest of Asia-Pacific: Market, by Animal Type, 2020-2027 (USD Million)
Table 154 Rest of Asia-Pacific: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 155 Number of Veterinarians and Veterinary Para-Professionals in Latin America (2016 Vs. 2019)
Table 156 Latin America: Market, by Indication, 2020-2027 (USD Million)
Table 157 Latin America: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 158 Latin America: Market, by Route of Administration, 2020-2027 (USD Million)
Table 159 Latin America: Market, by Animal Type, 2020-2027 (USD Million)
Table 160 Latin America: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 161 Middle East & Africa: Companion Animal Pharmaceuticals Market, by Indication, 2020-2027 (USD Million)
Table 162 Middle East & Africa: Market for Infectious Diseases, by Type, 2020-2027 (USD Million)
Table 163 Middle East & Africa: Market, by Route of Administration, 2020-2027 (USD Million)
Table 164 Middle East & Africa: Market, by Animal Type, 2020-2027 (USD Million)
Table 165 Middle East & Africa: Market, by Distribution Channel, 2020-2027 (USD Million)
Table 166 Market: Indication Portfolio Analysis:
Table 167 Market: Route of Administration Portfolio Analysis
Table 168 Market: Animal Type Portfolio Analysis
Table 169 Market: Distribution Channel Portfolio Analysis
Table 170 Market: Regional Revenue Mix
Table 171 Product Launches & Approvals
Table 172 Deals
Table 173 Other Developments
Table 174 Zoetis Inc.: Business Overview
Table 175 Merck & Co., Inc.: Business Overview
Table 176 Boehringer Ingelheim International GmbH: Business Overview
Table 177 Elanco Animal Health Incorporated: Business Overview
Table 178 Virbac: Business Overview
Table 179 Dechra Pharmaceuticals plc: Business Overview
Table 180 Vetoquinol: Business Overview
Table 181 Neogen Corporation: Business Overview
Table 182 Orion Group: Business Overview
Table 183 Eco Animal Health Group plc: Business Overview
List of Figures (61 Figures)
Figure 1 Companion Animal Pharmaceuticals Market Segmentation
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: by Company Type, Designation, and Region
Figure 4 Market Size Estimation: Revenue Share Analysis
Figure 5 Revenue Share Analysis Illustration: Zoetis Inc.
Figure 6 Market: Supply-Side Analysis
Figure 7 Market Analysis Approach
Figure 8 US: Market Approach
Figure 9 Top-Down Approach
Figure 10 CAGR Projections
Figure 11 Market (2022-2027): Impact Analysis on Drivers, Restraints, Opportunities, and Challenges
Figure 12 Data Triangulation Methodology
Figure 13 Market, by Indication, 2022 Vs. 2027 (USD Million)
Figure 14 Market, by Route of Administration, 2022 Vs. 2027 (USD Million)
Figure 15 Market, by Animal Type, 2022 Vs. 2027 (USD Million)
Figure 16 Market, by Distribution Channel, 2022 Vs. 2027 (USD Million)
Figure 17 Market: Geographical Snapshot
Figure 18 Increasing Prevalence of Zoonotic Diseases and Rising Pet Ownership Rates Worldwide to Drive Market
Figure 19 Infectious Diseases Segment in Germany Accounted for Largest Share in 2021
Figure 20 China & India to Register Highest Growth Rate During Forecast Period
Figure 21 Asia-Pacific to Witness Highest CAGR During Forecast Period
Figure 22 Emerging Markets to Register Higher Growth Rate During Forecast Period
Figure 23 Market: Drivers, Restraints, Opportunities, and Challenges
Figure 24 Canada: Average Annual Premiums (2017-2021)
Figure 25 US: Pet Industry Expenditure, 2010-2020
Figure 26 Companion Animal Pharmaceutical Market: Development and Approval Process for Products
Figure 27 Companion Animal Pharmaceutical Market: Product Approval Process in Europe
Figure 28 Market: Value Chain Analysis
Figure 29 Market: Supply Chain Analysis
Figure 30 Market: Ecosystem Analysis
Figure 31 Patent Publication Trends (January 2013-December 2022)
Figure 32 Market: Top Applicants (Companies/Institutions) for Patents (2017-2022)
Figure 33 Companion Animal Pharmaceutical Market: Top Applicant Countries for Patents (2017-2022)
Figure 34 Influence of Stakeholders in Buying Process for Top 3 Applications
Figure 35 Buying Criteria
Figure 36 Growing Pet Dog Population in India (Million)
Figure 37 Population of Pet Dogs Globally (Million)
Figure 38 Market: Geographic Snapshot
Figure 39 Expected Growth for Number of Veterinarians in North America (2012 Vs. 2030)
Figure 40 North America: Market Snapshot
Figure 41 US: Population of Dogs, 2012-2020 (Million)
Figure 42 US: Expenditure on Vet Visits, 2013-2020
Figure 43 Asia-Pacific: Market Snapshot
Figure 44 China: Projected Companion Animal Population, 2018-2025 (Million)
Figure 45 India: Projected Companion Animal Population, 2018-2025 (Million)
Figure 46 Australia: Projected Companion Animal Population, 2018-2025 (Million)
Figure 47 Key Player Strategies Adopted by Market Players (2019-2022)
Figure 48 Companion Animal Pharmaceuticals Market: Revenue Share Analysis of Top 5 Players (2017-2021)
Figure 49 Market Share, by Key Player (2021)
Figure 50 Market: Company Evaluation Quadrant (2021)
Figure 51 Market: Startups/Sme Evaluation Quadrant (2021)
Figure 52 Zoetis: Company Snapshot (2021)
Figure 53 Merck & Co., Inc.: Company Snapshot (2021)
Figure 54 Boehringer Ingelheim GmbH: Company Snapshot (2021)
Figure 55 Elanco Animal Health Incorporated: Company Snapshot (2021)
Figure 56 Virbac: Company Snapshot (2021)
Figure 57 Dechra Pharmaceuticals plc: Company Snapshot (2021)
Figure 58 Vetoquinol: Company Snapshot (2021)
Figure 59 Neogen Corporation: Company Snapshot (2021)
Figure 60 Orion Group: Company Snapshot (2021)
Figure 61 Eco Animal Health Group plc: Company Snapshot (2021)
Executive Summary
Companies Mentioned
- Analyst's View
- Ashish Life Science Pvt. Ltd.
- Biogenesis Bago S.A.
- Boehringer Ingelheim International GmbH
- Brilliant Biopharma
- Ceva Santé Animale
- Chanelle Pharma
- Dechra Pharmaceuticals plc
- Eco Animal Health Group plc
- Elanco Animal Health Incorporated
- Endovac Animal Health
- Hipra
- Indian Immunologicals Ltd.
- Intas Pharmaceuticals
- Kyoritsu Seiyaku
- Merck & Co., Inc.
- Neogen Corporation
- Norbrook
- Orion Group
- Pharma Pvt. Ltd.
- Tianjin Rinpu Bio-Technology Co., Ltd.
- Vetindia Pharmaceuticals Limited
- Vetoquinol
- Virbac
- Zenex Animal Health India Private Limited
- Zoetis Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 268 |
| Published | March 2023 |
| Forecast Period | 2022 - 2027 |
| Estimated Market Value ( USD | $ 14.4 Billion |
| Forecasted Market Value ( USD | $ 19.6 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
